This panel discussion discussed approaches to securing funding for new drug therapies used for relapsed disease and the decision-making process around the development and dissemination of these novel drug therapies. The panel presentation involved three different perspectives on cost and resource implications from a provincial, medical economics and hospital administration perspective.
Jaclyn Beca, MSc
Manager, Pharmaeconomics Research Unit
Cancer Care Ontario, Toronto
Suzanne McGurn, RN, BScN, MPA
Assistant Deputy Minister and Executive Officer
Ontario Public Drug Programs
Judy Van Clieaf, RN, BScN, MN
The Hospital for Sick Children
Note: POGO was not granted permission to share Jaclyn Beca’s or Judy Van Clieaf’s slides.